Janssen Pharma Inc v. Eugia Pharma Specialties Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Janssen Pharmaceuticals, Inc. (Pennsylvania) and Janssen Pharmaceutica NV (Belgium)
  • Defendant: Eugia Pharma Specialities Ltd. (India), Eugia US, LLC (Delaware), and Aurobindo Pharma USA, Inc. (Delaware)
  • Plaintiff's Counsel: Robinson Miller LLC
• Case Identification: 2:26-cv-03197, D.N.J., 03/25/2026
• Venue Allegations: Plaintiffs allege venue is proper in the District of New Jersey because Defendants Eugia US and Aurobindo USA have regular and established places of business in the district and have committed acts of infringement there. It is also alleged that all defendants have previously consented to or did not contest venue in the district in prior patent cases.
• Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the antipsychotic drug Invega Sustenna infringes a patent covering a specific dosing regimen for the drug.
• Technical Context: The technology concerns a long-acting injectable formulation of paliperidone palmitate, an antipsychotic medication used for treating schizophrenia, designed to improve patient compliance by replacing daily oral medication with monthly injections.
• Key Procedural History: The complaint notes prior litigation involving the patent-in-suit against other parties, which is currently before the U.S. Court of Appeals for the Federal Circuit.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,439,906 - Dosing Regimen Associated With Long Acting Injectable Paliperidone Esters

• Patent Identification: U.S. Patent No. 9,439,906, "Dosing Regimen Associated With Long Acting Injectable Paliperidone Esters," issued September 13, 2016.

The Invention Explained

• Problem Addressed: Long-acting injectable antipsychotics improve patient compliance, but achieving an optimal and stable therapeutic plasma concentration of the active drug (paliperidone) is challenging. The drug's absorption from the injection site is complex and can be too slow to be effective initially, potentially leading to treatment failure or relapse '906 Patent, col. 1:51-col. 2:7
• The Patented Solution: The patent discloses a specific initiation or "loading dose" regimen to solve this problem. It requires two initial injections with higher doses administered into the deltoid muscle-a location found to provide faster initial absorption-followed by subsequent, lower "maintenance" doses that can be administered in either the deltoid or gluteal muscle. This front-loading approach is designed to rapidly bring the patient's plasma concentration to a therapeutic level and then maintain it with once-monthly injections '906 Patent, abstract '906 Patent, col. 5:1-15
• Technical Importance: This dosing strategy was important for making long-acting injectables a viable and effective treatment option from the outset of therapy, mitigating the risk of sub-therapeutic dosing during the critical initial treatment period '906 Patent, col. 1:51-58

Key Claims at a Glance

• The complaint asserts infringement of claims 1-21 '906 Patent, claims 1-21 Compl. ¶36 Independent claim 1 is representative and contains the following essential elements:
  • A method for administering paliperidone palmitate to a psychiatric patient.
  • Administering a first loading dose of about 150 mg-eq. intramuscularly in the deltoid on the first day of treatment.
  • Administering a second loading dose of about 100 mg-eq. intramuscularly in the deltoid muscle on the 6th to about 10th day of treatment.
  • Administering a first maintenance dose of about 25 mg-eq. to about 150 mg-eq. intramuscularly in the deltoid or gluteal muscle a month (±7 days) after the second loading dose.
• The complaint does not single out specific dependent claims but reserves the right to assert them '906 Patent, claims 2-21 Compl. ¶36

III. The Accused Instrumentality

Product Identification

• The accused products are Defendants' proposed generic versions of Invega Sustenna (paliperidone palmitate) extended-release injectable suspension, as described in ANDA No. 221305 Compl. ¶2

Functionality and Market Context

• The proposed generic products are intended to be bioequivalent versions of Janssen's branded Invega Sustenna product, offered in various dosages including 39 mg, 78 mg, 117 mg, 156 mg, and 234 mg Compl. ¶10 Compl. ¶38 As an ANDA product, its proposed labeling is required to be the same as the FDA-approved labeling for the brand-name drug Compl. ¶46 The product is indicated for the treatment of schizophrenia and schizoaffective disorder in adults Compl. ¶34
• The complaint alleges that Defendants seek to market these generic products prior to the expiration of the '906 Patent Compl. ¶2

IV. Analysis of Infringement Allegations

The complaint alleges that the proposed labeling for Defendants' generic product will instruct medical professionals and patients to administer the drug using the patented dosing regimen, which gives rise to infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶44 Compl. ¶46

No probative visual evidence provided in complaint.

9,439,906 Patent Infringement Allegations

Identified Points of Contention

• Validity Questions: The core of the dispute will likely center on the validity of the '906 Patent. Defendants' Paragraph IV certification asserts that the patent claims are invalid, unenforceable, and/or not infringed Compl. ¶38 This raises the question of whether the claimed dosing regimen would have been obvious to a person of ordinary skill in the art at the time of the invention.
• Scope Questions: While infringement in an ANDA case is often straightforward if the patent is valid (as the generic label must match the branded one), a potential issue could arise from the term "about" as used for the dosage amounts. The analysis may explore whether the specific formulation in Defendants' ANDA could produce a clinical effect that arguably falls outside the scope of "about 150 mg-eq." or "about 100 mg-eq.," even if the label mirrors that of the branded product.

V. Key Claim Terms for Construction

• The Term: "about"
• Context and Importance: This term modifies all dosage amounts in claim 1 ("about 150 mg-eq.", "about 100 mg-eq.", etc.). The construction of "about" will define the permissible range of dosages covered by the claims. This is critical for determining the literal scope of the claims and whether any minor variations in the accused product's dosage or delivery mechanism fall inside or outside that scope.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent does not provide an explicit definition for "about." A party arguing for a broader scope may contend that the term should be given its ordinary meaning in the pharmaceutical arts, which generally implies a degree of acceptable variation or approximation inherent in drug manufacturing and administration.
  • Evidence for a Narrower Interpretation: The claims recite specific numerical values (150, 100). A party arguing for a narrower scope may point to the detailed pharmacokinetic modeling and clinical trial data discussed in the specification as evidence that these specific values were critical to achieving the desired plasma concentration profile, suggesting "about" should be construed narrowly to encompass only minor, insignificant deviations '906 Patent, col. 21:23-col. 22:42

VI. Other Allegations

• Indirect Infringement: The complaint alleges induced infringement, stating that Defendants will take active steps to encourage infringement by physicians and patients through the proposed product's labeling, which will instruct the use of the patented method Compl. ¶46 The complaint also pleads contributory infringement, alleging the proposed generic is not a staple article of commerce and is specifically designed for infringing use Compl. ¶47
• Willful Infringement: The complaint does not explicitly allege "willful infringement," but it does allege that Defendants have "actual knowledge of the 906 Patent" as evidenced by their ANDA Notice Letter Compl. ¶42 It also seeks a declaration that the case is "exceptional" under 35 U.S.C. § 285, which is the basis for awarding attorneys' fees, often in cases of willful or egregious conduct Compl. ¶50

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of patent validity: Will the claimed dosing regimen-a specific sequence of loading and maintenance doses administered in particular muscle groups-be found to be a non-obvious invention over the prior art related to long-acting injectables and antipsychotic treatments?
• A secondary issue, predicated on the patent's validity, will be one of statutory infringement: Does the act of filing an ANDA with a label that necessarily instructs the patented method constitute an act of infringement under 35 U.S.C. § 271(e)(2), and does the scientific data within the ANDA itself confirm that the proposed generic product will, in fact, be administered according to every limitation of the asserted claims?